Moneycontrol
Get App
Last Updated : Feb 09, 2017 11:52 AM IST | Source: CNBC-TV18

Aurobindo Q3 profit seen up 14%, revenue may grow 10% on US biz

Analysts believe lack of high value launches should keep US growth restricted. Drugs such as Nuvigil, Tricor, Valcyte, Vimpat and Vfend generic may drive US business. Within injectables drugs such as Isosulfane Blue may drive hospital sales in US.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Aurobindo Pharma is expected to report a 14.4 percent growth year-on-year in profit at Rs 612.12 crore and 10.3 percent in revenue at Rs 3,857.2 crore, driven by US business that contributes over 58 percent to formulation sales.


Operating profit is seen rising 14 percent to Rs 937 crore and margin may expand 80 basis points to 24.3 percent compared with year-ago quarter, according to average of estimates of analysts polled by CNBC-TV18.


Analysts believe lack of high value launches should keep US growth restricted. Drugs such as Nuvigil, Tricor, Valcyte, Vimpat and Vfend generic may drive US business. Within injectables drugs such as Isosulfane Blue may drive hospital sales in US.

Close

Injectables sales were USD 73 million in first half of FY17 and are expected to pick up on account of 3-4 recent launches.


Europe and Rest of the World businesses are estimated in grow in single digit while API is likely to grow around 5-6 percent YoY.


Commentary on free cash flow generation, reduction in net debt, integration plans for European portfolio acquired from Teva and acquisition of Portuguese company Generis Farmaceutica SA will be closely watched.



Exclusive offer: Use code "BUDGET2020" and get Moneycontrol Pro's Subscription for as little as Rs 333/- for the first year.

First Published on Feb 9, 2017 11:52 am
Sections
Follow us on